Guardant Health, Inc. Common Stock Canaccord Genuity's 46th Annual Growth Conference

Appreciate it. Yeah. Yeah. Thanks for having us.

Yeah. Once again, I think it shows a business that's really firing on all cylinders. We have these three overlapping S-curves, very large market opportunities that are all growing very rapidly. We had great growth with Guardant360 in our oncology business. That's our flagship therapy selection test. We saw over 30% year-over-year growth there. We saw even greater growth for our tissue test. It's really, I think, just the momentum we're seeing with the SmartIGR Platform, this really broad-based genomic, epigenomic platform we launched almost two years ago now, and we're continuing to see sort of that pay dividends in terms of continued volume growth and adoption. We're also seeing very good strength in our MRD business. This is the next market that we're in, the sort of $20 billion recurrence detection market. We have our product Guardant Reveal that has been doing really, really well.

It's been growing over 100% year-over-year. We recently launched a new indication for therapy monitoring there in November of last year, and we see really good growth with that market really drafting behind Guardant360 and the strength we have with oncologists. Then finally, with Shield, we're seeing, I think, continued very strong momentum there. One of the, if not the, probably most successful launch in diagnostics from both a volume and revenue point of view. We're seeing I think 50% quarter-over-quarter growth there and multi-100% year-over-year growth there. So, I think a lot to like about how the year has progressed so far.

On the therapy selection, on the liquid.

Reveal and Guardant360 tissue. Those right now are obviously smaller contributors to the overall business compared with Guardant360, which we launched in 2014.

But the fact that those are growing, I think, very rapidly bodes well for the coming years. We think tissue is going to be a pretty large segment for us as we continue to lean into it. What we're seeing is that that flywheel just takes time to gain speed, especially for a product like a tissue product that we have incumbents in there. There's I think legacy products that are out there.

As physicians start using it, trialing it, sampling it, and then they gain experience with our lower QNS rates, the comprehensiveness of the test, all the apps that we have on it, we're seeing that momentum build up, and it's something where I think we can continue to take share and build that up into a fairly sizable business. MRD, obviously, I think is still very much in its early innings. That's something where not only do we have, I think, the premier tissue-free MRD franchise right now, we're about to launch, this year, our first tumor-informed offering, Reveal Ultra. We will be probably the company with the most comprehensive offering in oncology in terms of liquid tissue, tumor-informed, tumor tissue-free.